OXIPEROMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H23N3O2
Molecular Weight	337.4155
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C1NC2=C(C=CC=C2)N1C3CCN(CCOC4=CC=CC=C4)CC3

InChI

InChIKey=NVDBBGBUTKLRSN-UHFFFAOYSA-N

InChI=1S/C20H23N3O2/c24-20-21-18-8-4-5-9-19(18)23(20)16-10-12-22(13-11-16)14-15-25-17-6-2-1-3-7-17/h1-9,16H,10-15H2,(H,21,24)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/638546 | https://www.ncbi.nlm.nih.gov/pubmed/7373324

Oxiperomide was developed as a dopamine-receptor antagonist. Clinical trials have shown that this drug decreased dyskinesia in patients with Parkinson's disease receiving levodopa or other dopamine agonists without necessarily increasing Parkinsonian symptoms. However, information about the further development of this drug is not available.

Approval Year

PubMed

Title	Date	PubMed
Neuroleptic-induced acute dyskinesias in rhesus monkeys.	1981	6117919
Oxiperomide in tardive dyskinesia.	1980-03	7373324
Blockade of apomorphine-induced aggression by morphine or neuroleptics: differential alteration by antimuscarinics and naloxone.	1976-06	988593

Patents

Sample Use Guides

In Vivo Use Guide

Oxiperomide was given in 5 mg tablet doses twice daily, starting at 10 mg/day and increasing weekly by 5-10 mg/day intervals, up to 40 mg/day, until an optimal dose was achieved or side effects developed.

Route of Administration: Oral

Name

Type

Language

NSC-313681

Preferred Name

English

OXIPEROMIDE

Official Name

English

oxiperomide [INN]

Common Name

English

OXIPEROMIDE [USAN]

Common Name

English

R-4714

Code

English

R 4714

Code

English

1-[1-(2-Phenoxyethyl)-4-piperidyl]-2-benzimidazolinone

Systematic Name

English

2H-BENZIMIDAZOL-2-ONE, 1,3-DIHYDRO-1-(1-(2-PHENOXYETHYL)-4-PIPERIDINYL)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C38149